Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.30 |
| ▸ | TUBB | P07437 | 1/20 | 0.30 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.30 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.30 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.30 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.30 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.30 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.30 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.30 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.30 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.30 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.30 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.30 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.30 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16455214 | 0.94 | TUBB4A (0.30) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL10248527 | 0.90 | — | — | |
| SCHEMBL806691 | 0.88 | GAA (0.33) | — | |
| SCHEMBL16455038 | 0.84 | TUBB4A (0.33) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL23736080 | 0.82 | HDAC3 (0.34) | — | |
| SCHEMBL15344705 | 0.81 | — | — | |
| SCHEMBL26508138 | 0.80 | PDE4B (0.31) | — | |
| SCHEMBL23605010 | 0.80 | PDE4B (0.31) | — | |
| SCHEMBL23605437 | 0.79 | REN (0.34) | — | |
| SCHEMBL15727144 | 0.78 | PDE4B (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297851-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2016-10-13 | — | — | US | disclosed |
| US-9187524-B2 | Broad spectrum antibiotic arylomycin analogs | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-11-17 | — | — | US | disclosed |
| US-20130281360-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | THE SCIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281360-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | SPAST, NPEPPS, SPATS2L | TUBB4A 4657/4885TUBB 4058/4885TUBA3C 4451/4885 |
| US-20160297851-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | SPAST, NPEPPS, SPATS2L | TUBB4A 4657/4885TUBB 4058/4885TUBA3C 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.